BRPI0516749B8 - composições compreendendo antagonistas dos receptores 5-ht2a e 5-ht6 e uso destes para o tratamento de distúrbios cognitivos - Google Patents
composições compreendendo antagonistas dos receptores 5-ht2a e 5-ht6 e uso destes para o tratamento de distúrbios cognitivosInfo
- Publication number
- BRPI0516749B8 BRPI0516749B8 BRPI0516749A BRPI0516749A BRPI0516749B8 BR PI0516749 B8 BRPI0516749 B8 BR PI0516749B8 BR PI0516749 A BRPI0516749 A BR PI0516749A BR PI0516749 A BRPI0516749 A BR PI0516749A BR PI0516749 B8 BRPI0516749 B8 BR PI0516749B8
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- ht2a
- cognitive disorders
- compositions
- receptor antagonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61470504P | 2004-09-30 | 2004-09-30 | |
US60/614,705 | 2004-09-30 | ||
PCT/EP2005/010251 WO2006037482A2 (en) | 2004-09-30 | 2005-09-22 | Compositions and methods for treating cognitive disorders |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0516749A BRPI0516749A (pt) | 2008-09-23 |
BRPI0516749B1 BRPI0516749B1 (pt) | 2019-08-06 |
BRPI0516749B8 true BRPI0516749B8 (pt) | 2021-05-25 |
Family
ID=35295334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0516749A BRPI0516749B8 (pt) | 2004-09-30 | 2005-09-22 | composições compreendendo antagonistas dos receptores 5-ht2a e 5-ht6 e uso destes para o tratamento de distúrbios cognitivos |
Country Status (14)
Country | Link |
---|---|
EP (2) | EP2301625B1 (pt) |
JP (2) | JP4975626B2 (pt) |
KR (2) | KR100993434B1 (pt) |
CN (3) | CN102114244A (pt) |
AT (1) | ATE499147T1 (pt) |
AU (2) | AU2005291542B2 (pt) |
BR (1) | BRPI0516749B8 (pt) |
CA (1) | CA2582273C (pt) |
DE (1) | DE602005026543D1 (pt) |
ES (3) | ES2348467T3 (pt) |
MX (1) | MX2007003545A (pt) |
RU (1) | RU2420318C2 (pt) |
WO (1) | WO2006037482A2 (pt) |
ZA (1) | ZA200702397B (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006037481A1 (en) * | 2004-09-30 | 2006-04-13 | F.Hoffmann-La Roche Ag | Benzoxazine and quinoxaline derivatives and uses |
CA2591937C (en) * | 2004-12-21 | 2013-08-06 | F. Hoffmann-La Roche Ag | Tetralin and indane derivatives and uses thereof |
CN101263136A (zh) * | 2005-07-13 | 2008-09-10 | 弗·哈夫曼-拉罗切有限公司 | 作为5-ht6、5-ht24的苯并咪唑衍生物 |
AU2007263084A1 (en) * | 2006-06-20 | 2007-12-27 | F. Hoffmann-La Roche Ag | Tetralin and indane derivatives and uses thereof |
DE602007012080D1 (de) * | 2007-08-01 | 2011-03-03 | Esteve Labor Dr | Kombination von mindestens zwei 5-HT6-Liganden |
EP3718547A1 (en) | 2011-10-03 | 2020-10-07 | The University of Utah Research Foundation | Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
KR101613245B1 (ko) | 2015-04-27 | 2016-04-18 | 주식회사 대웅제약 | 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
RU2624978C2 (ru) * | 2015-07-27 | 2017-07-11 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежский государственный медицинский университет им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации | Способ лечения умеренного когнитивного снижения |
CN108926565A (zh) * | 2017-05-26 | 2018-12-04 | 中国科学院上海生命科学研究院 | 五羟色胺受体亚型6小分子激活剂及拮抗剂在防治阿尔茨海默症中的应用 |
WO2019008484A1 (en) * | 2017-07-03 | 2019-01-10 | Suven Life Sciences Limited | NEW USES OF A PURE 5-HT6 RECEPTOR ANTAGONIST |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2837803A (en) | 1954-11-26 | 1958-06-10 | United Carr Fastener Corp | Fastening device |
US3550605A (en) | 1967-12-04 | 1970-12-29 | Bendix Corp | Fluid device with improved fan-in capability |
FR2510112A1 (fr) * | 1981-07-24 | 1983-01-28 | Roussel Uclaf | Nouveaux derives du 2-oxo-pyrid-3-yl ou piperidin-3-yl indole, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant |
FR2639942B1 (fr) | 1988-12-02 | 1991-03-29 | Sanofi Sa | Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant |
JPH0375744A (ja) * | 1989-08-18 | 1991-03-29 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料の処理方法 |
JP2869512B2 (ja) | 1990-06-01 | 1999-03-10 | メレルダウファーマスーティカルズ インコーポレイテッド | (+)―α―(2,3―ジメトキシフェニル)―1―[2―(4―フルオロフェニル)エチル]―4―ピペリジンメタノール |
US5939451A (en) * | 1996-06-28 | 1999-08-17 | Hoffmann-La Roche Inc. | Use of sulfonamides |
DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
JP2002511097A (ja) | 1997-07-11 | 2002-04-09 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 5−ht▲下6▼レセプターアンタゴニストであるスルホンアミド誘導体およびその製造方法 |
US20020099076A1 (en) * | 2000-05-25 | 2002-07-25 | Richard Scheyer D. | Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis |
ES2280546T3 (es) * | 2001-06-07 | 2007-09-16 | F. Hoffmann-La Roche Ag | Nuevos derivados de indol con afinidad por el receptor 5-ht6. |
DE60212841T2 (de) | 2001-06-15 | 2007-06-21 | F. Hoffmann-La Roche Ag | 4 piperazinylindolderivate mit affinität zum 5-ht6-rezeptor |
WO2003029238A1 (en) * | 2001-10-04 | 2003-04-10 | Wyeth | Chroman derivatives as 5-hydroxytryptamine-6 ligands |
DE60303376T2 (de) | 2002-05-13 | 2006-11-16 | F. Hoffmann-La Roche Ag | Benzoxazinderivate als 5-ht6-modulatoren und deren verwendungen |
GB0212399D0 (en) * | 2002-05-29 | 2002-07-10 | Glaxo Group Ltd | Compounds |
CA2485725A1 (en) | 2002-06-05 | 2003-12-18 | F. Hoffmann-La Roche Ag | 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders |
AU2003273855B2 (en) | 2002-09-17 | 2009-01-15 | F. Hoffmann-La Roche Ag | 2,7-substituted indoles and their use as 5-HT6 modulators |
KR20050073560A (ko) | 2002-10-18 | 2005-07-14 | 에프. 호프만-라 로슈 아게 | 5-ht6 수용체 친화성을 갖는 4-피페라진일 벤젠설폰일인돌 |
MXPA05004758A (es) * | 2002-11-08 | 2005-08-02 | Hoffmann La Roche | Benzoxazinonas sustituidas y uso de las mismas. |
CA2547764A1 (en) * | 2003-12-09 | 2005-06-30 | F.Hoffmann-La Roche Ag | Benzoxazine derivatives and uses thereof |
RU2006129464A (ru) * | 2004-01-16 | 2008-02-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | Производные 1-бензил-5-пиперазин-1-ил-3, 4-дигидро-1н-хиназолин-2-она и соответствующие производные 1н-бензо (1, 2, 6) тиадиазин-2, 2-диоксида и 1, 4-дигидробензо (1, 3)оксазин-2-она в качестве модуляторов рецептора 5-гидрокситриптамина (5нт) для лечения заболевания центральной нервной системы |
RU2372344C2 (ru) * | 2004-05-05 | 2009-11-10 | Ф. Хоффманн-Ля Рош Аг | Арилсульфонилбензодиоксаны, применяемые для модуляции 5-нт6 рецептора, 5-нт2a рецептора или и того, и другого |
WO2006037481A1 (en) * | 2004-09-30 | 2006-04-13 | F.Hoffmann-La Roche Ag | Benzoxazine and quinoxaline derivatives and uses |
CA2591937C (en) * | 2004-12-21 | 2013-08-06 | F. Hoffmann-La Roche Ag | Tetralin and indane derivatives and uses thereof |
CN101263136A (zh) * | 2005-07-13 | 2008-09-10 | 弗·哈夫曼-拉罗切有限公司 | 作为5-ht6、5-ht24的苯并咪唑衍生物 |
-
2005
- 2005-09-22 EP EP10178640.8A patent/EP2301625B1/en not_active Not-in-force
- 2005-09-22 CN CN2011100460020A patent/CN102114244A/zh active Pending
- 2005-09-22 DE DE602005026543T patent/DE602005026543D1/de active Active
- 2005-09-22 CN CN2005800333009A patent/CN101031338B/zh not_active Expired - Fee Related
- 2005-09-22 CA CA2582273A patent/CA2582273C/en active Active
- 2005-09-22 BR BRPI0516749A patent/BRPI0516749B8/pt not_active IP Right Cessation
- 2005-09-22 AU AU2005291542A patent/AU2005291542B2/en active Active
- 2005-09-22 ES ES05796666T patent/ES2348467T3/es active Active
- 2005-09-22 KR KR1020087026939A patent/KR100993434B1/ko active IP Right Grant
- 2005-09-22 ES ES10178640.8T patent/ES2643615T3/es active Active
- 2005-09-22 ES ES05796070T patent/ES2359725T3/es active Active
- 2005-09-22 MX MX2007003545A patent/MX2007003545A/es active IP Right Grant
- 2005-09-22 RU RU2007110482/15A patent/RU2420318C2/ru active
- 2005-09-22 EP EP05796070A patent/EP1799306B1/en not_active Not-in-force
- 2005-09-22 JP JP2007533919A patent/JP4975626B2/ja not_active Expired - Fee Related
- 2005-09-22 KR KR1020077007141A patent/KR100941527B1/ko active IP Right Grant
- 2005-09-22 CN CNA2005800333066A patent/CN101031554A/zh active Pending
- 2005-09-22 AT AT05796070T patent/ATE499147T1/de active
- 2005-09-22 WO PCT/EP2005/010251 patent/WO2006037482A2/en active Application Filing
-
2007
- 2007-03-22 ZA ZA200702397A patent/ZA200702397B/xx unknown
-
2010
- 2010-12-17 AU AU2010257272A patent/AU2010257272B2/en active Active
-
2011
- 2011-04-12 JP JP2011088392A patent/JP5443429B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0516749B8 (pt) | composições compreendendo antagonistas dos receptores 5-ht2a e 5-ht6 e uso destes para o tratamento de distúrbios cognitivos | |
DK1531822T3 (da) | 1-aryl-4-substituerede piperazin derivater til anvendelse som CCR1 antagonister til behandlingen af inflammation og immunforstyrrelser | |
WO2007002293A3 (en) | Azaindazole compounds and methods of use | |
NO20034122L (no) | Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte | |
ECSP066468A (es) | Antagonistas de receptores muscarínicos de acetilcolina | |
PT1513826E (pt) | Novos derivados de indolilpiperidina como agentes anti-histaminicos e antialergicos potentes | |
ECSP045519A (es) | Nuevos derivados de quinuclidina-amida | |
PT1208095E (pt) | Dibenzopiranos como antagonistas dos receptores de glucorticoides para o tratamento de diabetes | |
BRPI0212137A2 (pt) | diidropteridinonas, processos para prepará-las e seu uso como composições farmacêuticas | |
PA8720801A1 (es) | Nuevas combinaciones terapeuticas para el tratamiento de la depresion | |
WO2007022257A3 (en) | Monocyclic and bicyclic compounds and methods of use | |
ATE455756T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
WO2007044885A3 (en) | Piperidine derivatives and methods of use | |
EE200300524A (et) | Ühendid, mis on CB2-retseptori agonistid, neid sisaldavad ravimkoostised ja nimetatud ühendite kasutamine ravis | |
BRPI0615163A2 (pt) | composto, composição farmacêutica, uso do composto, e, métodos de tratamento de distúrbios mediados por mglur5 e para inibição da ativação de receptores de mglur5 | |
IL179611A (en) | History 1-Aza-bicycloalkyl, their process, their pharmaceutical preparations and their use in the preparation of drugs for the treatment of psychotic disorders | |
DE602005005456D1 (de) | Neue azabicyclische derivate, herstellungsverfahren dafür und sie enthaltende pharmazeutische zusammensetzungen | |
BRPI0510024A (pt) | compostos e composições como modulares de ppar | |
AR025883A1 (es) | Utilizacion de antagonistas de los receptores de los cannabinoides centrales para la preparacion de medicamentos | |
CL2013001885A1 (es) | Compuestos derivados de morfina, antagonistas del receptor ipiode periferico; composicion farmaceutica; formulacion oral; y uso para reducir los efectos colaterales de la terapia opioide (div. sol. 905-08). | |
EP2155203A4 (en) | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | |
BRPI0414558A (pt) | composição farmacêutica compreendendo um antagonista do receptor p2x7 e uma droga antiinflamatória não esteróide | |
PA8720601A1 (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevenciòn de trastornos psicoticos | |
EA200602154A1 (ru) | Пиридин-4-илэтинилимидазолы и -пиразолы как антагонисты рецептора mglu5 | |
DE60306138D1 (de) | Azaindolylpiperidinderivate als antihistaminika und antiallergika |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 31/352 (2006.01), A61P 25/28 (2006.01), A61P |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/09/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2741 DE 18-07-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |